Valeant Claims Progress, Asks Investors For Patience

The Canadian specialty pharma has exceeded its near-term debt-reduction goals, but are its plans for a return to growth grounded in reality? Market analysts recommend caution, but see some reason for optimism.

Business Balance - A businessman carrying paperwork walking over a tight rope.

Valeant Pharmaceuticals International Inc. has made important debt-reduction progress, meeting its goal ahead of schedule, but the company's near-term growth story remains lackluster. The company told investors during a fourth quarter sales and earnings call that revenues will continue to decline in 2018, but pointed to a "significant seven" of newer products and some yet-to-be-approved opportunities that will drive its return to sales growth from 2019 through 2021.

The Laval, Quebec, specialty pharma still faces massive debt – although most now has been pushed back several years –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.